secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2022-10-26T23:59:59+00:00
Accession:  0001564590-22-035271
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics Q3 net loss $15.8M ($0.21/sh); cash $155M; three clinical data reads in 2023
--------------------------------------------------------------------------------

- Net loss of $15.8M ($0.21 per share) vs $13.2M ($0.17) in Q3 2021; nine-month net loss $49.3M ($0.64) vs $42.6M ($0.55).
- Cash, cash equivalents and short-term investments $155M, down from $202M at year-end 2021.
- VK2809 VOYAGE Phase 2b for NASH/fibrosis enrollment to finish Q4 2022; primary endpoint data 1H 2023.
- Phase 1 data for dual GLP-1/GIP agonist VK2735 expected early 2023; Phase 1b VK0214 for X-ALD data in 1H 2023.
- R&D expense $12.0M in Q3 vs $10.8M a year ago; G&A $4.2M vs $2.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022035271/0001564590-22-035271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022035271/vktx-8k_20221026.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-035271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer